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BACKGROUND:The standard treatment of choice for malignant pleural mesothelioma is chemotherapy with pemetrexed and platinum,
but the clinical outcome is poor. This study investigates the response to pemetrexed in a panel of eight mesothelioma cell lines and
the clinical outcome for patients treated with pemetrexed in relation to folate receptor alpha (FRa).
METHODS: Cell lines were treated with pemetrexed to determine the concentration that reduced growth to 50% (GI50). FRa
expression was determined by western blotting and that of FRa, reduced folate carrier (RFC) and proton-coupled folate transporter
(PCFT) by real-time quantitative RT–PCR. Immunohistochemistry for FRa was carried out on 62 paraffin-embedded samples of
mesothelioma from patients who were subsequently treated with pemetrexed.
RESULTS: A wide range of GI50 values was obtained for the cell lines, H2452 cells being the most sensitive (GI50 22nM) and RS5 cells
having a GI50 value greater than 10mM.N oF R a protein was detected in any cell line, and there was no relationship between
sensitivity and expression of folate transporters. FRa was detected in 39% of tumour samples, generally in a small percentage of cells.
There was no correlation between the presence of FRa and the outcome of pemetrexed treatment, and no significant difference
between histological subtypes.
CONCLUSION: Response to treatment with pemetrexed does not depend on the presence of FRa.
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Malignant pleural mesothelioma (MPM) is an aggressive tumour of
the pleura and usually has a poor prognosis. It is increasing in
many countries worldwide as a result of widespread exposure to
asbestos in the past and is expected to peak around 2015 in the
United Kingdom (Hodgson et al, 2005). The disease affects more
men than women in a ratio of 5:1 and tends to have a long latency
period of 20–40 years after asbestos exposure, affecting people in
the fifth to seventh decade of life. Approximately 80% of MPM is
attributed to exposure to asbestos fibres, although some tumours
are ‘spontaneous’ with no evidence of asbestos exposure. The
outcome of patients with MPM is generally poor, with a median
survival of 6–12 months. Most patients are unsuitable for radical
surgery. Radiation therapy has been shown to alleviate pain in the
majority of treated patients, but the duration of symptom control
is short lived, hence chemotherapy is generally the treatment of
choice. Clinical trials have shown a partial response rate of 32%
using a combination of pemetrexed and carboplatin (Hughes
et al, 2002). A phase III trial using pemetrexed with cisplatin
significantly improved response rates, time to progression, overall
survival and quality of life, compared with single agent cisplatin,
and suggested that this be used as front-line chemotherapy in
MPM patients (Vogelzang et al, 2003). Response rate in this study
was 41%, with a median survival benefit of 2.8 months, but relapse
rates remain high and long-term survival is poor; therefore,
improved patient selection for treatment in this disease is still
required.
Pemetrexed is a multitargeted antifolate that inhibits several
enzymes important in folate metabolism, the main action being on
thymidylate synthetase (TS). Inhibition of TS leads to depleted
levels of thymidine, which are crucial to DNA synthesis.
Pemetrexed also inhibits, to a lesser degree, glycinamide
ribonucleotide formyltransferase (GARFT) (Shih et al, 1997). Once
in the cell, pemetrexed undergoes polyglutamation, often resulting
in a tri- or penta-glutamate tail being added to the parent drug.
This process is facilitated by the enzyme folyl-poly glutamate
synthetase (FPGS), for which pemetrexed has a high affinity, and
results in cellular drug retention. The affinity of pemetrexed to TS
is also increased by at least 60 times in the polyglutamated form,
compared with the parent drug (Hanauske et al, 2001).
Folic acid and antifolates enter cells by three mechanisms. The
reduced folate carrier (RFC) is a bidirectional anion exchanger that
has a high affinity for reduced folate co-factors and antifolates, but
a low affinity for folic acid. It has a neutral pH optimum and is
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subiquitously expressed (Whetstine et al, 2002). The folate receptor
alpha (FRa) is an energy-dependent high-affinity, low-capacity
folate-binding protein that delivers folates and antifolates into
cells. The low capacity is due to endocytosis of the receptor that
has to return to the cell surface in order to function. Expression is
limited to specific tissues and is expressed in a characteristic
distribution, for example, on syncytiotrophoblastic cells of the
placenta and the proximal convoluted tubule of the kidney
(Weitman et al, 1992; Mantovani et al, 1994). However, FRa has
been reported to be highly expressed in some malignancies: in 90%
of non-mucinous epithelial ovarian cancers (Toffoli et al, 1997)
and in 72% of malignant mesotheliomas (Bueno et al, 2001). Folate
receptor alpha has been believed to be important for the
physiological transport of folic acid, but not generally for
antifolates (Kamen and Smith, 2004). However, there is evidence
to suggest that FRa may have an important role in folate and
antifolate transport under certain circumstances. Studies per-
formed on vulval epithelial cell lines A431 and A431-FBP, a highly
expressing FRa transfectant, showed that A431-FBP was approxi-
mately three-fold more sensitive to pemetrexed than the isogenic
non-FRa-expressing cell line when cells were maintained in a
physiological level of folate (20nM leucovorin) and was 14-fold
more sensitive when maintained in sub-physiological levels (1nM
leucovorin) (Theti and Jackman, 2004). Membrane transport of
folates has also been recently reported to occur through a
ubiquitously expressed proton-coupled folate transporter (PCFT)
(Wang et al, 2003; Zhao et al, 2008), a low-pH transporter with a
high affinity for pemetrexed.
The contribution of FRa to pemetrexed transport is likely to be
significant in cells in which FRa is highly expressed. In these
situations, transport of pemetrexed via FRa may enhance delivery
of the drug to the tumour and potentially enhance response.
Recently, a new monoclonal FRa antibody has been developed that
can be used for immunohistochemistry on formalin-fixed paraffin-
embedded (FFPE) tissues (Smith et al, 2007) and therefore be more
widely used on stored and more readily transportable tumour
specimens. This study investigates the growth inhibitory effects of
pemetrexed in eight human mesothelioma cell lines and their FRa
status. It also reports the response to treatment with pemetrexed in
mesothelioma patients in relation to FRa immunohistochemistry
of the tumours.
MATERIALS AND METHODS
Cell culture
Eight human mesothelioma cell lines were used in this study. Five
cell lines were of epithelioid type: NCI-H28 (H28), NCI-H2052
(2052), NCI-H2452 (2452) (ATCC, Manassas, VA, USA), NCI-H226
(H226) (Cancer Research, London, UK) and JL1 (DSMZ, Braunschweig,
Germany); MSTO-211H (MSTO) (ATCC) was of biphasic origin;
two cell lines, DM3 and RS5 (DSMZ) were of sarcomatoid type.
Cells were grown in RPMI 1640 (R8758, Sigma–Aldrich, Poole,
UK) containing 2mM glutamine, 1.5gl
 1 sodium bicarbonate,
4.5gl
 1 glucose, 10mM HEPES, 1mM sodium pyruvate and either
10% foetal bovine serum (FBS) (Sigma-Aldrich) or 10% dialysed
FBS (DFBS) (Invitrogen, Faisley, UK). Dialysis of serum removes
low molecular weight compounds such as thymidine and homo-
cysteine, which may affect the response of cells to pemetrexed.
The concentration of folic acid in the medium used is 2mM. All cell
lines were subcultured regularly and were negative for mycoplasma.
Growth-inhibition studies using pemetrexed were carried out
using the SulfurRhodamine B (SRB) (Skehan et al, 1990) assay in
96-well tissue culture plates as previously described (Nutt et al,
2004). Cells were seeded at 5 10
3 cells per well and treated with
10nM to 10mM pemetrexed for approximately three cell doubling
times, apart from the slower growing RS5 and DM3 cells that were
treated for 6 days. The concentration of pemetrexed resulting in
50% growth inhibition (GI50) for each cell line was calculated using
GraphPad Prism software.
Cell lysates required for western blotting were prepared after
washing cells with ice-cold PBS and addition of lysis buffer
(62.5mM Tris/HCl pH 6.8, 2% sodium dodecyl sulphate and 10%
glycerol).
Western blotting
Western blotting was carried out to determine the presence and
level of expression of FRa protein. Cell lysates were prepared and
20mg aliquots of protein (calculated from quantification using the
Pierce BCA protein assay) from each sample were loaded on a 4–
20% gradient polyacrylamide gel (Invitrogen). After SDS–PAGE
and electroblotting (Towbin et al, 1979), membranes were treated
for 1h with TBS-Tween buffer containing 5% milk to block non-
specific binding and then incubated with a previously described
and validated monoclonal mouse FRa primary antibody (Smith
et al, 2007) for 1h at room temperature. Secondary HRP-conjugated
antibody (goat anti-mouse, Dako, Ely, UK) was used to detect
the primary antibodies and antibody-labelled protein bands were
visualised by enhanced chemiluminescent detection (ECL) (GE
Healthcare, Little Chalfont, UK). Equal loading of protein was
verified using a mouse anti-tubulin antibody (Sigma–Aldrich).
IGROV1 (an ovarian cancer cell line) cell lysate was used as a
positive control and Jurkat cell lysate was used as a negative
control for FRa.
Quantitative RT–PCR
RNA was extracted from cells using the Qiagen RNAeasy minikit
(Qiagen, Hilden, Germany) and reverse transcribed using TaqMan
reverse transcriptase reagents (Applied Biosystems, Warrington, UK).
A volume of 2.5ml cDNA was used for quantitative real-time PCR
in a total volume of 10ml, repeated in triplicate, using the TaqMan
gene expression assay Hs00357143_g1 for FRa, Hs00953344_m1
for RFC, Hs00611082_m1 for PCFT and Hs99999901_s1 for 18S
(all from Applied Biosystems), as well as universal mastermix.
The expected amplicon sizes were 89, 106, 72 and 187, respectively.
PCR was performed as follows: 501C for 2min, 951C for 10min,
and 40 cycles of 951C for 15s and 601C for 1min using the ABI
Prism 7900HT sequence detection system (Applied Biosystems).
Results were quantified relative to 18S, and calibrated to the
IGROV1 FRa estimation.
Immunohistochemistry and clinical correlation
Eligible patients were identified from chemotherapy prescription
records. All patients underwent histological diagnosis of malignant
pleural mesothelioma and were treated according to our institu-
tional protocol, in which carboplatin was administered to produce
a value of the area under the curve (AUC) of 5, i.v. over 30min on
day 1 (or cisplatin 75mgm
 2, i.v. administered over 3h on day 1)
and pemetrexed administered at a dose of 500mgm
 2 i.v. for
10min on day 1. Cycles were repeated every 21 days to a maximum
of six cycles. Patients also received folic acid supplementation at a
dose of 400mg daily, beginning at least 7 days before the first dose
of pemetrexed and one injection of 1000mg vitamin B12
intramuscularly 7–14 days before beginning the treatment. Folic
acid was continued, and vitamin B12 was repeated every 12 weeks,
throughout the treatment until 21 days after the last dose of
pemetrexed. Dexamethasone, 4mg twice daily, was given orally on
the day before, the day of and the day after therapy. Our antiemetic
regimen included a serotonin antagonist. Chemotherapy was
discontinued in the event of disease progression, unacceptable
toxicity or after completion of six cycles. Cycles were repeated
at 100% of the intended doses if neutrophil and platelet counts
were X1.5 10
9l
 1 and X100 10
9l
 1, respectively. If any dose
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sreduction occurred, patients continued to receive the reduced dose
throughout their treatment. All patients underwent planned
radiographic evaluation.
Sections of 4mm were cut from FFPE tissue blocks of identified
patients and mounted on SuperFrost Plus microscope slides (VWR
International, Lutterworth, UK) and allowed to dry at 561C. The
slides were dewaxed in xylene, rehydrated in graded ethanol and
incubated for 10min in 0.5% hydrogen peroxide solution to block
endogenous peroxidase activity. The slides were then treated with
an endogenous biotin blocking kit (Dako) before high-temperature
antigen retrieval (microwaved thrice for 5min in citrate buffer
pH 6.0). Blocking with a 1 in 5 dilution of normal goat serum
for 10min preceded overnight incubation in a 1 in 20 dilution
of FRa antibody (Smith et al, 2007) at 41C. Detection of the
primary antibody was carried out using biotinylated goat anti-
mouse secondary antibody and was visualised using DAB. Between
each incubation step, slides were rinsed in TBS pH 7.6 for
2 5min washes. Negative controls with no primary antibody
were used and a FFPE section of renal tissue was used as a positive
control.
Staining was graded independently by two assessors (JN and
AR) using a composite index. The intensity of staining was scored
0–3, with 0 being no staining, 1 weak staining, 2 moderate staining
and 3 intense staining. This was multiplied by the percentage of
tumour area stained, using 10 for upto 10%, 25 for 11–25%, 50 for
26–50%, 75 for 51–75% and 100 for 76–100% of the tumour area
stained, giving a composite score range of 0–300. The staining
obtained in the renal tissue was used as a reference for intense
staining, with a score of 300.
The composite score for the FRa immunohistochemistry of
tumour samples was correlated to clinical parameters such as
response (objective decrease in tumour size on CT imaging),
disease control rate (DCR, presence of stable disease or better on
CT), time-to-treatment failure (TTF, time from treatment initiation
to documented clinical or radiological progression) and overall
survival (OS, time from treatment initiation to death from any
cause).
This study was approved by the local research ethics committee
and the Newcastle Hospitals Caldicott Guardian.
RESULTS
Cell culture
Pemetrexed inhibited the growth of mesothelioma cell lines to
variable extents. Representative graphs showing patterns of growth
inhibition for each cell line in medium containing FBS or DFBS are
shown in Figure 1. The mean GI50±s.d. value from three replicate
experiments is shown in Table 1. GI50 values ranged from 14nM in
the H2452 epithelioid cell line to greater than 10mM in the
sarcomatoid cell line RS5. In most cases, apart from sarcomatoid
RS5 cells, those grown in medium containing DFBS were more
sensitive to pemetrexed than cells grown in medium containing
normal FBS, with the largest difference observed in JL1 and DM3
cell lines. This is probably because of the removal of molecules
such as folates, thymidine and homocysteine from the serum on
dialysis, which are able to rescue cells from the effects of
pemetrexed.
Western blotting and quantitative RT–PCR
The results for western blotting and quantitative RT–PCR are
shown in Figure 2. In western blotting, there was no evidence of
any FRa protein in any of the mesothelioma cell lines, but was
shown to be present at high levels in the IGROV1 ovarian cell line
positive control. Similarly, the results from real-time PCR showed
FRa mRNA to be undetectable in three cell lines (JL1, DM3 and
RS5), whereas extremely low levels at the limit of detection were
present in the other mesothelioma cell lines. In these cell lines, the
level of expression for FRa was approximately 100 times less than
the highly expressing IGROV1 ovarian cancer cell line.
The results from real-time RT–PCR for other folate transpor-
ters, RFC and PCFT, in the cell lines are shown in Figure 3. The
relative expression of both these transporters varied between the
cell lines, with the most variation observed in RFC. There was no
correlation between RFC and PCFT with the GI50 of pemetrexed in
the cell lines.
Immunohistochemistry and clinical correlation
In all, 62 patients were eligible for this study. A summary of
demographics and treatment details is shown in Table 2.
A sample of the positive control and various staining intensities
are depicted in Figure 4. FRa expression was considered to be
positive when the composite score was 40. FRa expression was
positive in 24 of the 62 samples examined (39%, composite score
range: 5–142.5). Both membranous and cytoplasmic staining was
seen. When present, however, FRa expression was usually weak as
12 (50%) stained samples had a score of 30 or less. Only two
samples had a composite score of more than 100. FRa expression
was seen to be higher in the epithelioid disease subtype but was
not significant (epithelioid, n¼16 (44%), biphasic, n¼6 (35%)
and sarcomatoid, n¼2 (22%),  
2 1.614, P¼0.45).
There were no significant differences in the proportion of
patients with a response or disease control when subdivided into
those with a positive or negative expression of FRa. Responses
were seen in 8 (33%) and 9 (24%) patients with positive and
negative FRa-stained tumours (P¼0.56, Fisher’s exact test),
whereas 75 and 61%, respectively, had disease control (P¼0.28,
Fisher’s exact test). The TTF and OS rates were not statistically
different between patients with positive FRa tumours and those
that were negative (median TTF 7.4 vs 5.1 and OS 10.4 vs 8.6
months, log rank P¼0.61 and 0.74, respectively), as shown in
Figure 5. The results in terms of treatment response, DCRs, TTF
and OS were similar when comparing higher expression (compo-
site score 430) against low or no expression of FRa.
DISCUSSION
Antifolates have been developed over the years to inhibit a number
of folate-dependent enzymes. Methotrexate primarily targets
dihydrofolate reductase, raltitrexed targets thymidylate synthase
and the more recently introduced pemetrexed has multiple targets
in the folate pathway. The role of FRa in the uptake of both folates
(essential for cellular purine and pyrimidine biosynthesis and
eventually DNA synthesis) and antifolates has been the subject of
numerous publications with contrasting results (Chattopadhyay
et al, 2004; Theti and Jackman, 2004). Chemotherapy for
mesothelioma, using pemetrexed and platinum, is now the
standard treatment of choice. In mesothelioma, FRa has been
described as highly activated (Bueno et al, 2001), with 72% of 61
mesotheliomas showing a two- to four-fold higher mRNA
expression compared with normal control tissues. Immunohisto-
chemical studies using Mov 18 and Mov 19 antibodies on frozen
sections confirmed the results by demonstrating FRa at the cellular
membrane in 13 of 17 samples. However, a later study (Khokhar
et al, 2002) demonstrated that despite some expression of FRa in
human mesothelioma cells, internalisation of methotrexate was
predominantly carrier mediated. A highly variable expression of
both RFC and FRa was found by RT–PCR in a number of
mesothelioma samples. With the development of a novel FRa
antibody for use in paraffin-embedded tissues, in this paper, the
role of FRa in stored mesothelioma samples has been related to the
response of treatment to pemetrexed. The effect of pemetrexed in
FRa and pemetrexed in mesothelioma
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srelation to FRa in a selection of mesothelioma cell lines has also
been established.
The panel of mesothelioma cell lines used included cells of both
epithelioid and sarcomatoid types. Generally, tumours of the
sarcomatoid type are less responsive to chemotherapy. This was
reflected in the sensitivity of cell lines to continuous pemetrexed
treatment, which showed that sarcomatoid cell lines (RS5 and
DM3) were less sensitive to pemetrexed than the other cell lines.
Clinically, sarcomatoid tumours tend to be more aggressive than
epithelioid tumours (Herndon et al, 1998). In RPMI medium,
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Figure 1 Effect of pemetrexed on growth of mesothelioma cell lines grown in medium containing foetal bovine serum (FBS) (solid line) or dialysed foetal
bovine serum (DFBS) (dashed line) with s.d. (n¼6) for one representative experiment.
Table 1 Mean GI50 values (nM)±s.d. (n¼3) for pemetrexed in mesothelioma cell lines grown in medium containing foetal bovine serum (FBS) or
dialysed FBS (DFBS)
Cell line MSTO H28 H226 D2052 D2452 JL1 DM3 RS5
GI50 in FBS medium (nM) 33.6±6.2 82.4±3.2 41000 24±22 2 ±3 41000 410000 410000
GI50 in DFBS medium (nM) 27.1±6.4 46.5±3.1 257.3±38 16±11 4 ±1 102±27 205±96 410000
FRa and pemetrexed in mesothelioma
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ssarcomatoid cells were also slower growing (with doubling times of
3–4 days) than epithelioid cells (with doubling times of 1–2 days).
A recent report on cell proliferation rates in samples of
mesothelioma, using the Ki-67 proliferation index (PI), showed
that biphasic tumours had a higher PI than epithelioid and
sarcomatoid types, and that the median value for epithelioid
samples was higher than that of sarcomatoid tumours (Cakir et al,
2006), although only 4.5% of tumours were of the sarcomatoid type.
In all cell lines in which a GI50 value was reached, this value was
lower when DFBS, rather than normal FBS, was used in the
medium. This will have been due to removal of small molecules
such as folates, thymidine and homocysteine from the serum on
dialysis. A report using pemetrexed and gemcitabine in the NCI-
MSTO 211H cell line showed a two-fold higher pemetrexed GI50
value of 67nM (Nagai et al, 2008), compared with the value
reported here, and strong synergism was observed in these
cells when pemetrexed preceded dosing with gemcitabine. Other
studies found that the sensitivity of mesothelioma cell lines
after 8h exposure to 30mM pemetrexed was in the order
H20524H284MSTO-211H, and that caffeine enhanced peme-
trexed activity in the mesothelioma cell lines tested (Min et al,
2008). Similar differences in pemetrexed sensitivity have also been
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Figure 2 (A) Western blot analysis of folate receptor alpha (FRa) in mesothelioma cell lysates. IGROV1 was used as a positive control and Jurkat as a
negative control. Tubulin antibody shows equal loading in all lanes. Each antibody showed a single band, as shown in the cropped gels. (B) Quantification of
FRa mRNA by real-time PCR in mesothelioma cell lines relative to FRa-positive IGROV1 cells.
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Figure 3 Quantification of reduced folate carrier (RFC) and proton-
coupled folate transporter (PCFT) mRNA by real-time PCR in mesothe-
lioma cell lines relative to IGROV1 cells. Error bars show s.d., n¼3.
Table 2 Patient, disease and treatment demographics
Parameters n (%)
Median age, range 65.6, 49–82
Gender
Male/Female 49 (79)/13 (21)
Histology
Epithelioid 36 (58)
Biphasic 17 (27)
Sarcomatoid 9 (15)
Stage
1/2/3/4 4 (6)/16 (26)/32 (52)/10 (16)
WHO PS
0/1/2 8 (13)/36 (58)/18 (29)
Chemotherapy regimen
Pemetrexed/Carboplatin 45 (73)
Pemetrexed/Cisplatin 12 (27)
Median chemotherapy cycles (range) 4 (2–6)
FRa and pemetrexed in mesothelioma
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sreported (Chattopadhyay et al, 2006) between H28 and H2052 cells
(GI50 values 90 and 40nM, respectively). It has been reported that
the effect of pemetrexed is enhanced in cell lines when there is a
low or physiological concentration of folate in the medium (Theti
and Jackman, 2004) and that higher extra-cellular folate levels
correlate inversely with pemetrexed activity in vitro in mesothe-
lioma and other solid tumour cell lines (Chattopadhyay et al,
2007). In our studies, it was found that when using normal or low-
folate medium (results using low-folate medium are not shown)
and dialysed or normal serum, the main difference in the effect of
pemetrexed was seen between the dialysed serum and normal
serum as reported here; hence, low-folate medium was not
routinely used.
The RFC, rather than PCFT, shows the most variation in cell
lines. There was no correlation between RFC or PCFT with the GI50
for pemetrexed. However, a higher RFC was seen in less sensitive
cells, apart from the sensitive MSTO cells.
The ratio of epithelioid to sarcomatoid cell lines used in this
study reflects the general occurrence of these different tumour
types, the majority being epithelioid, 10–15% sarcomatoid and
20–35% biphasic. All cell lines used retained their typical
epithelioid or sarcomatoid morphology, using FBS in the medium.
Cells are generally grown in medium containing bovine serum, but
no changes in morphology were seen, unlike the report of
mesothelioma cell lines of different morphology (Klominek et al,
1989) established from the pleural fluid of one patient.
Folate receptor alpha was unable to be detected in western
blots in any mesothelioma cell line, and was also only barely
detectable by real-time PCR. It is therefore evident that
the difference in sensitivity to pemetrexed in cell lines is not due
10 m
Figure 4 Folate receptor alpha (FRa) immunohistochemistry staining of samples of (A) renal tissue used as positive control; (B–D) mesothelioma
samples showing weak (B), moderate (C) and strong (D) staining.
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Figure 5 (A) Kaplan–Meier time-to-treatment failure (TTF) curves. (B) Kaplan–Meier overall survival (OS) curves. Solid line indicates samples with
negative folate receptor alpha (FRa) expression (n¼38), dashed line indicates positive FRa expression (n¼24).
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sto the presence of FRa and the uptake of pemetrexed into the cells
through FRa.
A review on FRa (Kelemen, 2006) suggests that further research
into the presence of FRa in tumours is necessary, as there is a lack
of clinical studies using tumour samples, particularly in the
context of pemetrexed trials. Until recently, there has been no
antibody available to detect FRa by immunohistochemistry in
paraffin-embedded tumour samples, although the antibodies
Mov18 and Mov19 could be used on frozen sections (Bueno
et al, 2001). Another study of FRa in samples of mesothelioma
(Khokhar et al, 2002) showed no difference in FRa gene expression
(by RT-RNA) in mesothelioma of differing histological type.
Following the development of an FRa antibody for use on paraffin-
embedded tissues (Smith et al, 2007), samples of mesothelioma
have been used in this study for FRa immunohistochemistry and
the results have been compared with response to treatment with
pemetrexed. The protein was only detected in 39% of tumours,
which is lower than in the previous study, and staining was both
membranous and cytoplasmic. Focal staining was generally
observed in small regions of tumours, involving only a small
percentage of tumour cells and only in two cases was the staining
intense. There was no significant difference in FRa staining
between the three histological subtypes of mesothelioma, and no
difference was observed in the overall survival or time to treatment
failure for patients with positive FRa tumours compared with
those with negative FRa tumours. FRa is therefore unlikely to have
a major role in the uptake of pemetrexed in mesothelioma and
what little expression there is does not seem to be a predictive
marker for treatment response. The low levels of FRa expression in
malignant pleural mesothelioma samples and the lack of relation-
ship to pemetrexed treatment in this series are consistent with the
cell culture observations.
The large differences in response to pemetrexed warrant further
investigation. A recent report now provides evidence that the
secondary target for the effect of pemetrexed is aminoimidazole-
carboxamide ribonucleotide formyl-transferase (AICART), in-
volved in de novo purine synthesis, rather than GARFT,
(Racanelli et al, 2009), and this may explain the unusual activity
of pemetrexed in lung cancers.
In conclusion, the use of a varied panel of eight mesothelioma
cell lines and the investigation of a large number of tumour
samples from patients with mesothelioma treated with pemetrexed
in this study demonstrate that there is no relationship between
response to pemetrexed and FRa expression in mesothelioma, or
to the expression of RFC and PCFT in the cell lines. Other reasons
for differences in sensitivity to pemetrexed remain to be
established, but this study shows that there is no simple
relationship between the sensitivity of cell lines to pemetrexed
and the expression of any of the folate transporters; other potential
molecular markers for pemetrexed response in mesothelioma are
currently under investigation.
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